Kamil Ali Jackson is Chief Legal Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 160,214 shares of ACRS, which is worth approximately $189,052. The most recent transaction as insider was on Jan 03, 2022, when has been sold 45,518 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 160K
0% 3M change
0% 12M change
Total Value Held $189,052

Kamil Ali-Jackson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 03 2022
BUY
Exercise of conversion of derivative security
-
45,518 Added 22.12%
160,214 Common Stock
Jun 03 2021
SELL
Open market or private sale
$208,444 $21.96 p/Share
9,492 Reduced 7.21%
122,196 Common Stock
Jun 02 2021
SELL
Open market or private sale
$659,907 $21.91 p/Share
30,119 Reduced 18.61%
131,688 Common Stock
Jun 01 2021
SELL
Open market or private sale
$347,250 $23.15 p/Share
15,000 Reduced 8.48%
161,807 Common Stock
Jun 01 2021
BUY
Exercise of conversion of derivative security
-
33,189 Added 15.8%
176,807 Common Stock
May 07 2021
SELL
Open market or private sale
$127,872 $23.61 p/Share
5,416 Reduced 3.63%
143,618 Common Stock
May 07 2021
BUY
Exercise of conversion of derivative security
$57,735 $10.66 p/Share
5,416 Added 3.51%
149,034 Common Stock
May 06 2021
SELL
Open market or private sale
$353,850 $23.59 p/Share
15,000 Reduced 9.46%
143,618 Common Stock
May 06 2021
BUY
Exercise of conversion of derivative security
$159,900 $10.66 p/Share
15,000 Added 8.64%
158,618 Common Stock
May 05 2021
SELL
Open market or private sale
$362,550 $24.17 p/Share
15,000 Reduced 9.46%
143,618 Common Stock
May 05 2021
BUY
Exercise of conversion of derivative security
$159,900 $10.66 p/Share
15,000 Added 8.64%
158,618 Common Stock
May 04 2021
SELL
Open market or private sale
$360,600 $24.04 p/Share
15,000 Reduced 9.46%
143,618 Common Stock
May 04 2021
BUY
Exercise of conversion of derivative security
$159,900 $10.66 p/Share
15,000 Added 8.64%
158,618 Common Stock
May 03 2021
SELL
Open market or private sale
$370,200 $24.68 p/Share
15,000 Reduced 9.46%
143,618 Common Stock
May 03 2021
BUY
Exercise of conversion of derivative security
$159,900 $10.66 p/Share
15,000 Added 8.64%
158,618 Common Stock
Mar 11 2021
SELL
Bona fide gift
-
7,500 Reduced 6.14%
114,696 Common Stock
Mar 02 2021
SELL
Payment of exercise price or tax liability
$44,314 $23.25 p/Share
1,906 Reduced 1.31%
143,618 Common Stock
Mar 02 2021
BUY
Exercise of conversion of derivative security
-
6,637 Added 4.36%
145,524 Common Stock
Mar 01 2021
SELL
Payment of exercise price or tax liability
$118,712 $24.06 p/Share
4,934 Reduced 3.43%
138,887 Common Stock
Mar 01 2021
BUY
Exercise of conversion of derivative security
-
17,175 Added 10.67%
143,821 Common Stock
Feb 01 2021
SELL
Payment of exercise price or tax liability
$28,139 $21.35 p/Share
1,318 Reduced 1.03%
126,646 Common Stock
Feb 01 2021
BUY
Exercise of conversion of derivative security
-
3,875 Added 2.94%
127,964 Common Stock
Dec 15 2020
SELL
Payment of exercise price or tax liability
$2,286 $4.59 p/Share
498 Reduced 0.4%
124,089 Common Stock
Dec 15 2020
BUY
Exercise of conversion of derivative security
-
1,734 Added 1.37%
124,587 Common Stock

Also insider at

PDSB
PDS Biotechnology Corp Healthcare
RIGL
RIGEL PHARMACEUTICALS INC Healthcare
KA

Kamil Ali Jackson

Chief Legal Officer
Wayne, PA

Track Institutional and Insider Activities on ACRS

Follow Aclaris Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS